File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Mifepristone: A potential postcoital contraceptive

TitleMifepristone: A potential postcoital contraceptive
Authors
KeywordsEmergency contraception
Mifepristone
Postcoital contraception
Issue Date2001
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop
Citation
Expert Opinion On Pharmacotherapy, 2001, v. 2 n. 9, p. 1383-1388 How to Cite?
AbstractMifepristone is an orally-active progesterone receptor antagonist. When a single dose of mifepristone is given in the mid- or late follicular phase, it may diminish or inhibit the luteinising hormone (LH) surge. In the early luteal phase, a single dose of mifepristone induces significant changes in the endometrium without affecting the hormonal levels or menstruation. When it is given in the mid-luteal phase, there will also be significant changes in the endometrium and some women may have two episodes of vaginal bleeding. A clinical trial suggests that a single dose of mifepristone in the early luteal phase may be an effective contraceptive agent but the lack of a cheap and easy method to identify the LH surge limits its clinical application. The administration of mifepristone alone or in combination with a prostaglandin does not appear to be an effective form of contraception. When used together with a prostaglandin, it may be an effective method for menstrual regulation but the cost and possible side effects of the prostaglandins limit its use. Mifepristone is a very effective method for emergency contraception. The incidence of side effects was also lower than that of the Yuzpe regimen. Lowering the dose of mifepristone from 600 to 10 mg does not decrease its efficacy but the incidence of delay in onset of the subsequent menses is reduced. Despite its efficacy, the reputation of mifepristone as an abortion pill may limit its access in many countries.
Persistent Identifierhttp://hdl.handle.net/10722/87277
ISSN
2015 Impact Factor: 3.543
2015 SCImago Journal Rankings: 0.884
References

 

DC FieldValueLanguage
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2010-09-06T09:27:37Z-
dc.date.available2010-09-06T09:27:37Z-
dc.date.issued2001en_HK
dc.identifier.citationExpert Opinion On Pharmacotherapy, 2001, v. 2 n. 9, p. 1383-1388en_HK
dc.identifier.issn1465-6566en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87277-
dc.description.abstractMifepristone is an orally-active progesterone receptor antagonist. When a single dose of mifepristone is given in the mid- or late follicular phase, it may diminish or inhibit the luteinising hormone (LH) surge. In the early luteal phase, a single dose of mifepristone induces significant changes in the endometrium without affecting the hormonal levels or menstruation. When it is given in the mid-luteal phase, there will also be significant changes in the endometrium and some women may have two episodes of vaginal bleeding. A clinical trial suggests that a single dose of mifepristone in the early luteal phase may be an effective contraceptive agent but the lack of a cheap and easy method to identify the LH surge limits its clinical application. The administration of mifepristone alone or in combination with a prostaglandin does not appear to be an effective form of contraception. When used together with a prostaglandin, it may be an effective method for menstrual regulation but the cost and possible side effects of the prostaglandins limit its use. Mifepristone is a very effective method for emergency contraception. The incidence of side effects was also lower than that of the Yuzpe regimen. Lowering the dose of mifepristone from 600 to 10 mg does not decrease its efficacy but the incidence of delay in onset of the subsequent menses is reduced. Despite its efficacy, the reputation of mifepristone as an abortion pill may limit its access in many countries.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eopen_HK
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_HK
dc.rightsExpert Opinion on Pharmacotherapy. Copyright © Informa Healthcare.en_HK
dc.subjectEmergency contraceptionen_HK
dc.subjectMifepristoneen_HK
dc.subjectPostcoital contraceptionen_HK
dc.titleMifepristone: A potential postcoital contraceptiveen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1465-6566&volume=2&issue=9&spage=1383&epage=1388&date=2001&atitle=Mifepristone:+a+potential+postcoital+contraceptiveen_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14656566.2.9.1383en_HK
dc.identifier.pmid11585018-
dc.identifier.scopuseid_2-s2.0-0034839419en_HK
dc.identifier.hkuros65373en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034839419&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume2en_HK
dc.identifier.issue9en_HK
dc.identifier.spage1383en_HK
dc.identifier.epage1388en_HK
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats